Norinchukin Bank The lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 65.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 10,771 shares of the company’s stock after acquiring an additional 4,276 shares during the quarter. Norinchukin Bank The’s holdings in IDEXX Laboratories were worth $1,684,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in IDXX. FMR LLC raised its position in shares of IDEXX Laboratories by 2.6% during the second quarter. FMR LLC now owns 37,353 shares of the company’s stock worth $6,030,000 after purchasing an additional 934 shares during the period. Oakbrook Investments LLC raised its position in shares of IDEXX Laboratories by 27.0% during the third quarter. Oakbrook Investments LLC now owns 4,230 shares of the company’s stock worth $658,000 after purchasing an additional 900 shares during the period. APG Asset Management N.V. raised its position in shares of IDEXX Laboratories by 150.5% during the third quarter. APG Asset Management N.V. now owns 215,200 shares of the company’s stock worth $33,461,000 after purchasing an additional 129,300 shares during the period. Advisors Capital Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $262,000. Finally, Xact Kapitalforvaltning AB raised its position in IDEXX Laboratories by 5.5% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 12,697 shares of the company’s stock valued at $1,974,000 after buying an additional 662 shares during the last quarter. 86.02% of the stock is currently owned by institutional investors.
A number of equities research analysts recently issued reports on IDXX shares. Piper Jaffray Companies started coverage on IDEXX Laboratories in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 target price on the stock. BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America lifted their target price on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Finally, Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of “Buy” and an average price target of $194.00.
In related news, Director Bruce L. Claflin purchased 1,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were purchased at an average price of $179.58 per share, with a total value of $179,580.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $179,580. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William T. End sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $184.48, for a total value of $737,920.00. Following the transaction, the director now directly owns 41,256 shares in the company, valued at approximately $7,610,906.88. The disclosure for this sale can be found here. Insiders have sold a total of 90,762 shares of company stock worth $15,940,404 in the last ninety days. Insiders own 2.77% of the company’s stock.
Shares of IDEXX Laboratories, Inc. (IDXX) opened at $187.61 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $141.02 and a 1 year high of $198.73. The stock has a market capitalization of $16,018.40, a P/E ratio of 63.81, a P/E/G ratio of 2.26 and a beta of 0.58. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The business had revenue of $506.00 million for the quarter, compared to analyst estimates of $490.51 million. During the same quarter last year, the firm earned $0.58 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.2% compared to the same quarter last year. equities analysts expect that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/24/idexx-laboratories-inc-idxx-shares-bought-by-norinchukin-bank-the.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.